Introduction 7 cytoplasmic calcium in a dose-dependent manner ( Fig. 2A-C) . In many cases, calcium waves 141 were observed in individual keratinocytes (Fig. 2-S1) , an activation pattern that induces the 142 calcium/calcineurin-dependent transcription factor NFAT to translocate to the nucleus and direct 
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To test the hypothesis that NFAT is activated downstream of CWO treatment in 146 keratinocytes, we analyzed nuclear translocation of NFATc1, an isoform with well documented 147 activity in human keratinocytes ( Fig. 2D) Tripathi et al., 2014) . Keratinocytes treated in vitro with 0.02-0.04% CWO displayed 149 significant translocation of NFATc1 without compromising cell viability ( Fig. 2-S2 ). This effect was 150 completely eliminated by pre-treatment with CSA, indicating that NFAT translocation was 151 dependent on calcium/calcineurin signaling ( Fig. 2E) . Thus, we conclude that CWO induces 152 NFAT translocation through calcium/calcineurin signaling in keratinocytes.
153
NFAT activity has context-dependent effects on keratinocyte proliferation, both 154 maintaining stem cell quiescence and inducing keratinocyte proliferation (Goldstein et al., 2014, 
155
Horsley, Aliprantis, 2008, Keyes et al., 2013 , Tripathi, Wang, 2014 . We postulated that CWO 156 might also alter the cell cycle through NFAT activity. We noted that CWO application induces mild Given that CWO induces calcium signaling and proliferation in keratinocytes, we 167 hypothesized that it might work through TRPV3, a calcium channel which is expressed in 168 keratinocytes and is activated by camphor and related terpenes (Borbiro et al., 2011, Vogt-Eisele, 169 Weber, 2007) . To test whether TRPV3 is required for CWO's effects in the skin, we performed in 170 vivo proliferation assays on TRPV3 knockout animals and wild-type littermates (Fig. 3) . TRPV3 171 disruption had no effect on CWO-meditated proliferation; therefore, we conclude that the effects 172 of CWO are not TRPV3 dependent.
173 174 CWO treatment induces immune-dependent tumor clearance. We next took an unbiased, 175 genome-wide approach to identify genetic pathways involved in CWO-induced tumor regression.
176
To this end, we performed RNA-sequencing of CWO-treated mouse tissues. Samples were 177 harvested from pre-malignant tumors collected after six weeks of treatment with vehicle or CWO 178 (N=3 mice per group, 4 pooled tumors per mouse). To identify targets directly downstream of 179 CWO activity in the skin, RNA-sequencing was also performed on epidermis isolated 24 h after a 180 single treatment with CWO or vehicle. We identified 293 genes differentially expressed in CWO-181 treated tumors and 1677 transcripts altered in CWO-treated epidermis (Fig. 4A ). Seventy-seven 182 genes were common in both datasets. We compared biological processes significantly altered in 183 both tissues by CWO treatment. These included several processes that influence tumor biology, 184 including blood vessel/vasculature development, skin development and cell death (Fig. 4A) .
185
Interestingly, several enriched nodes were consistent with an effect on immune regulation 186 including: cellular response to cytokines, granulocyte migration, and leukocyte chemotaxis. Based 187 on this intriguing finding, we postulated that CWO treatment of keratinocytes stimulates immune-188 cell recruitment, a mechanism that could lead to engulfment of tumor cells. To explore this 189 possibility, we analyzed gene ontology (GO) terms enriched in each tissue group separately with 190 a focus on immune pathways ( Fig. 4-S1 ). CWO treatment of tumors stimulated inflammatory 191 response and chemotaxis pathways. Additionally, myeloid leukocyte migration and T cell 192 9 migration pathways were significantly enriched in epidermis. These findings, along with the 193 striking effect on regression of existing tumors, suggest that CWO stimulates a T cell-mediated 194 immune responses.
195
To dissect the dependence of CWO's anti-tumor effects on immune substrates, we tested 196 the necessity for CD4+ and CD8+ T cells, which are lymphocyte subsets commonly associated 197 with anti-tumor immunity. CD4+ T helper (T H ) cells activate and promote immune responses by 198 releasing cytokines, priming CD8+ T cells, and activating antigen presenting cells. Upon 199 activation, CD8+ cytotoxic T cells directly kill cancerous cells (Shiku, 2003) . Tumors were 200 chemically induced and then mice were randomly assigned to one of four treatment groups: 201 vehicle with isotype control injections, CWO with isotype control injections, CWO with CD8 202 blocking antibody, and CWO with CD4 blocking antibody. Mice received daily topical treatments 203 with CWO or vehicle along with weekly injections with antibodies or isotype (IgG) controls 204 ( Fig. 4B) . The effects of CWO treatment were completely reversed by administering a CD8-205 blocking monoclonal antibody ( Fig. 4C) , which was effective in reducing CD8+ circulating cells 206 up to 6 days after each application ( Fig. 4-S2A ). CD4 blocking antibodies appeared to have an 207 intermediate effect on CWO activity ( Fig. 4-S2B) ; however, CD4+ cells were present at sacrificing, 208 indicating that this population was not fully depleted by antibody treatment (Fig. 4-S2 ).
209
Collectively, these data suggest that CWO-mediated tumor regression is dependent on CD8+ 210 cytotoxic T cells.
212
Identification of CWO's active ingredients and effective concentrations. Finally, we sought 213 to determine active compounds in CWO that stimulate tumor regression. As a natural plant 214 derivative, CWO's mixture of terpenes varies depending on terroir (Satyal, Paudel, 2013) . Using 215 gas chromatography-mass spec (GC-MS), we found that many structurally related terpenes were 216 present in CWO, with eucalyptol and d,l-limonene being the most abundant constituents (Fig.
217
5A). As expected due to distillation, camphor was identified only in trace quantities in CWO and 10 is thus not expected to be an active ingredient. To test whether individual constituents recapitulate 219 the anti-tumor effects of CWO, tumors were induced as before and matched cohorts were treated 220 with one of five terpenes (eucalyptol, d,l-limonene, a-pinene, g-terpinene, and camphene; N=5 221 mice per group). Compounds were chosen based on abundance in CWO, confidence of 222 identification in GC-MS (>90% matching to reference compounds) and commercial availability of 223 purified chemicals. Mice received daily topical treatments with compounds at 20% dilutions (w/w) 224 in acetone vehicle for five weeks. Both d,l-limonene and a-pinene had significantly fewer lesions 225 than vehicle application, whereas mice treated with eucalyptol, g-terpinene, or camphene did not 226 differ from vehicle controls ( Fig. 5-S1 ). Thus, we conclude that d,l-limonene and/or a-pinene likely 227 mediate the antitumor effects of CWO.
228
We next sought to identify effective concentrations of terpenes for tumor reduction in vivo.
229
Tumor-bearing mice were split into matched groups and treated daily with a range of 230 concentrations of CWO, d,l-limonene, or a-pinene (0-40%; N=5 mice per group). CWO was 231 rapidly effective at high concentrations (40%; Fig. 5B ), with significant reduction in tumor burden 232 achieved within one week ( Fig. 5C) . In pilot studies, 40% solutions of either d,l-limonene or a-233 pinene produced marked skin irritation or toxicity; thus, these chemicals were applied up to 20% 234 ( Fig. 5D) . D,l-limonene produced the largest reduction in skin tumors at 20%, which was apparent 235 two weeks after the start of treatment ( Fig. 5D-E) . By contrast, 2.5% a-pinene resulted in 236 significant reductions in tumor burden ( Fig. 5F-G) . Interestingly, higher concentrations of 237 a-pinene did not reduce lesions in this cohort. Together, these results indicate that, compared 238 with a-pinene or d,l-limonene, camphor essential oil is better tolerated and leads to more rapid 239 reduction in tumor load. This finding implies that naturally derived CWO contains additional 
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and is a solvent in household cleaning products. The scent of pine is conferred by a-pinene in 258 household products, and g-terpinene is used in cosmetics. Thus, humans are frequently exposed 259 to these compounds, which are well tolerated on skin. We identified a-pinene and d,l-limonene 260 as active compounds that promote tumor regression. Future studies are needed to assess 261 whether these components act synergistically or separately on molecular pathways. The 262 prominence of CWO constituents in common household items poses an interesting avenue for 263 future investigation into whether exposure to these terpenes over a life-span alters the risk for Russin, Hoesly, 1989) . Extracts of C. camphora and related species are reported to be 269 cytotoxic to human tumor cells in vitro (Liu, Chen, 2011 , Satyal, Paudel, 2013 . Consistent with 270 our observations, D-limonene has been reported to have preventive effects on pre-malignant 271 lesion formation in a mouse model of cSCC (Chaudhary, Siddiqui, 2012) . Inhalation of α-pinene 272 has been suggested to reduce melanoma growth in mouse models (Kusuhara, Urakami, 2012) . 
291
Limonene and a-pinene have anti-tumor effects provide a starting point for future studies to 292 identify receptors that link CWO's active ingredients to NFAT signaling. 13 We propose that CWO stimulates tumor regression in skin through NFAT-dependent 294 signaling and CD8+ T cell-dependent mechanisms (Fig. 6) . Consistent with the involvement of 295 NFAT signaling, our in vitro studies demonstrated that CWO induced calcium signaling and 296 calcium/calcineurin-dependent NFAT translocation in human keratinocytes.
297
The effects of NFAT signaling in keratinocytes are multifaceted and context dependent. 
305
How can increased keratinocyte proliferation be reconciled with tumor regression? One 306 possibility is that CWO causes normal keratinocytes to proliferate and outcompete cancer stem 307 cells for metabolic resources. Alternatively, NFAT activation could differentially affect normal and 308 cancer stem cells, promoting proliferation in the former and quiescence in the later (Tripathi, 
309
Wang, 2014, Wu, Nguyen, 2010). Collectively, this alteration in proliferative potential could tip the 310 scale to promote tumor regression.
311
Our finding that immune cells are required for CWO's antitumor effects in vivo favor 
439
RNA-sequencing of tumors was initiated using a published DMBA-TPA protocol as minutes, 100-120 C for 10 minutes, 120-220 C for 6 minutes with a 50 C/minute ramp up rate.
468
Data were matched to existing library spectra. Treatment week -2 0 2 4 6 8 10 12 14 16 
731
A. Gas-chromatography mass spectrometry analysis of CWO. Percentage of constituent present 732 in CWO is shown on the pie chart and the percentage match to reference is shown in parentheses.
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One compound did not match well to reference. Week 0
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